Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Coronary risk of patients with valvular heart disease: prospective validation of CT-Valve Score

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Catheter ablation and mortality, stroke and heart failure readmission with atrial fibrillation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Long-term impact of baseline anaemia on clinical outcomes following percutaneous coronary intervention in stable angina

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Living with heart failure: perspectives of ethnic minority families

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Incidence of acute myocardial infarction-related cardiogenic shock during corona virus disease 19 (COVID-19) pandemic

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Hypertension, cardiovascular disease and cause of death in Danish living kidney donors: matched cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Catheter ablation and mortality, stroke and heart failure readmission with atrial fibrillation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: To prospectively validate the CT-Valve score, a new risk score designed to identify patients with valvular heart disease at a low risk of coronary artery disease (CAD) who could benefit from multislice CT (MSCT) first instead of coronary angiography (CAG).

METHODS: This was a prospective cohort study of patients referred for valve surgery in the Capital Region of Denmark and Odense University Hospital from the 1 February 2015 to the 1 February 2017. MSCT was implemented for patients with a CT-Valve score ≤7 at the referring physician's discretion. Patients with a history of CAD or chronic kidney disease were excluded. The primary outcome was the proportion of patients needing reevaluation with CAG after MSCT and risk of CAD among the patients determined to be low to intermediate risk.

RESULTS: In total, 1149 patients were included. The median score was 9 (IQR 3) and 339 (30%) had a score ≤7. MSCT was used for 117 patients. Of these 29 (25%) were reevaluated and 9 (7.7%) had CAD. Of the 222 patients with a score ≤7 that did not receive an MSCT, 14 (6%) had significant CAD. The estimated total cost of evaluation among patients with a score ≤7 before implementation was €132 093 compared with €79 073 after, a 40% reduction. Similarly, estimated total radiation before and after was 608 mSv and 362 mSv, a 41% reduction. Follow-up at a median of 32 months (18-48) showed no ischaemic events for patients receiving only MSCT.

CONCLUSION: The CT-Valve score is a valid method for determining risk of CAD among patients with valvular heart disease. Using a score ≤7 as a cut-off for the use of MSCT is safe and cost-effective.

OriginalsprogEngelsk
Artikelnummere001380
TidsskriftOpen Heart
Vol/bind7
Udgave nummer2
ISSN2053-3624
DOI
StatusUdgivet - okt. 2020

Bibliografisk note

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

ID: 61009662